Shopping Cart 0
Cart Subtotal
USD 0

Constellation Pharmaceuticals Inc (CNST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Constellation Pharmaceuticals Inc (Constellation) is a clinical biopharmaceutical company that focuses to develop novel therapeutics for the treatment of serious unmet medical needs in patients with cancers associated with abnormal gene expression. The company's pipeline products include CPI-1205, which is under clinical trials for the treatment of metastatic castration-resistant prostate cancer; CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis and CPI-0209, which is in preclinical trials for the treatment of solid tumors and/or hematological malignancies. It utilizes integrated epigenetics platform that enables it to validate targets and generate small molecules against the targets that modulate gene expression in tumor and immune cells. Constellation is headquartered in Cambridge, Massachusetts, the US.

Constellation Pharmaceuticals Inc (CNST)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Constellation Pharma Raises USD100 Million in Financing 10

Constellation Pharma Raises USD24.3 Million in Venture Financing 12

Constellation Pharma Raises USD55 Million Financing 13

Constellation Pharma Raises USD5 Million in Venture Financing 15

Partnerships 16

Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 16

Constellation Pharma Enters into Co-Development Agreement With Genentech 18

Equity Offering 19

Constellation Pharma Prices IPO of Shares for USD60 Million 19

Constellation Pharmaceuticals Inc-Key Competitors 20

Constellation Pharmaceuticals Inc-Key Employees 21

Constellation Pharmaceuticals Inc-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Aug 14, 2018: Constellation Pharmaceuticals announces second-quarter and six-month 2018 financial results 23

Corporate Communications 25

Sep 04, 2018: Constellation Pharmaceuticals Announces Appointments to Board of Directors 25

Oct 24, 2017: Constellation Pharmaceuticals Completes Management Team with Key Leadership Appointments 26

Jul 18, 2017: Constellation Pharmaceuticals Appoints Adrian Senderowicz, M.D., as Senior Vice President and Chief Medical Officer 27

May 25, 2017: Jigar Raythatha Rejoins Constellation Pharmaceuticals as President and CEO 28

Product News 29

12/12/2017: Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer 29

01/16/2018: Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 30

Clinical Trials 31

Jun 15, 2018: Researchers find combination can enhance ipilimumab immunotherapy 31

Feb 09, 2018: Constellation Pharmaceuticals Announces Upcoming Presentation on its Anti-Neoplastic Drug Candidate CPI-1205 33

Feb 09, 2018: Constellation Pharmaceuticals Announces Upcoming Presentations on its Anti-Cancer Drug Candidate CPI-0610 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Constellation Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Constellation Pharma Raises USD100 Million in Financing 10

Constellation Pharma Raises USD24.3 Million in Venture Financing 12

Constellation Pharma Raises USD55 Million Financing 13

Constellation Pharma Raises USD5 Million in Venture Financing 15

Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 16

Constellation Pharma Enters into Co-Development Agreement With Genentech 18

Constellation Pharma Prices IPO of Shares for USD60 Million 19

Constellation Pharmaceuticals Inc, Key Competitors 20

Constellation Pharmaceuticals Inc, Key Employees 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Constellation Pharmaceuticals Inc (Constellation) is a clinical biopharmaceutical company that focuses to develop novel therapeutics for the treatment of serious unmet medical needs in patients with cancers associated with abnormal gene expression. The company's pipeline products include CPI-1205, which is under clinical trials for the treatment of metastatic castration-resistant prostate cancer; CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis and CPI-0209, which is in preclinical trials for the treatment of solid tumors and/or hematological malignancies. It utilizes integrated epigenetics platform that enables it to validate targets and generate small molecules against the targets that modulate gene expression in tumor and immune cells. Constellation is headquartered in Cambridge, Massachusetts, the US.

Constellation Pharmaceuticals Inc (CNST)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Constellation Pharma Raises USD100 Million in Financing 10

Constellation Pharma Raises USD24.3 Million in Venture Financing 12

Constellation Pharma Raises USD55 Million Financing 13

Constellation Pharma Raises USD5 Million in Venture Financing 15

Partnerships 16

Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 16

Constellation Pharma Enters into Co-Development Agreement With Genentech 18

Equity Offering 19

Constellation Pharma Prices IPO of Shares for USD60 Million 19

Constellation Pharmaceuticals Inc-Key Competitors 20

Constellation Pharmaceuticals Inc-Key Employees 21

Constellation Pharmaceuticals Inc-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Aug 14, 2018: Constellation Pharmaceuticals announces second-quarter and six-month 2018 financial results 23

Corporate Communications 25

Sep 04, 2018: Constellation Pharmaceuticals Announces Appointments to Board of Directors 25

Oct 24, 2017: Constellation Pharmaceuticals Completes Management Team with Key Leadership Appointments 26

Jul 18, 2017: Constellation Pharmaceuticals Appoints Adrian Senderowicz, M.D., as Senior Vice President and Chief Medical Officer 27

May 25, 2017: Jigar Raythatha Rejoins Constellation Pharmaceuticals as President and CEO 28

Product News 29

12/12/2017: Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer 29

01/16/2018: Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 30

Clinical Trials 31

Jun 15, 2018: Researchers find combination can enhance ipilimumab immunotherapy 31

Feb 09, 2018: Constellation Pharmaceuticals Announces Upcoming Presentation on its Anti-Neoplastic Drug Candidate CPI-1205 33

Feb 09, 2018: Constellation Pharmaceuticals Announces Upcoming Presentations on its Anti-Cancer Drug Candidate CPI-0610 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Constellation Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Constellation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Constellation Pharma Raises USD100 Million in Financing 10

Constellation Pharma Raises USD24.3 Million in Venture Financing 12

Constellation Pharma Raises USD55 Million Financing 13

Constellation Pharma Raises USD5 Million in Venture Financing 15

Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 16

Constellation Pharma Enters into Co-Development Agreement With Genentech 18

Constellation Pharma Prices IPO of Shares for USD60 Million 19

Constellation Pharmaceuticals Inc, Key Competitors 20

Constellation Pharmaceuticals Inc, Key Employees 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS